JPMorgan Chase & Co. lowered its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 21.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 142,051 shares of the biopharmaceutical company’s stock after selling 38,261 shares during the period. JPMorgan Chase & Co.’s holdings in Vanda Pharmaceuticals were worth $1,989,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. State Street Corp increased its position in shares of Vanda Pharmaceuticals by 27.2% in the fourth quarter. State Street Corp now owns 1,751,605 shares of the biopharmaceutical company’s stock valued at $27,935,000 after buying an additional 374,095 shares in the last quarter. FMR LLC increased its position in shares of Vanda Pharmaceuticals by 928.0% in the fourth quarter. FMR LLC now owns 996,271 shares of the biopharmaceutical company’s stock valued at $15,891,000 after buying an additional 899,358 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Vanda Pharmaceuticals by 31.5% in the fourth quarter. Renaissance Technologies LLC now owns 568,350 shares of the biopharmaceutical company’s stock valued at $9,065,000 after buying an additional 136,300 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at about $223,000. Finally, Teachers Advisors LLC increased its position in shares of Vanda Pharmaceuticals by 8.0% in the fourth quarter. Teachers Advisors LLC now owns 530,681 shares of the biopharmaceutical company’s stock valued at $8,464,000 after buying an additional 39,340 shares in the last quarter. 92.51% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Inc. (NASDAQ VNDA) opened at 16.40 on Tuesday. Vanda Pharmaceuticals Inc. has a 52 week low of $10.81 and a 52 week high of $18.00. The firm has a 50 day moving average of $14.44 and a 200-day moving average of $14.49. The company’s market capitalization is $730.65 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by $0.04. Vanda Pharmaceuticals had a negative net margin of 8.85% and a negative return on equity of 10.42%. The company had revenue of $37.42 million during the quarter, compared to analyst estimates of $38.35 million. On average, analysts forecast that Vanda Pharmaceuticals Inc. will post ($0.70) earnings per share for the current year.

WARNING: This piece of content was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/07/18/jpmorgan-chase-co-decreases-stake-in-vanda-pharmaceuticals-inc-nasdaqvnda.html.

Several equities analysts recently issued reports on VNDA shares. Oppenheimer Holdings, Inc. started coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, April 12th. They set an “outperform” rating and a $21.00 price target for the company. CIBC reaffirmed an “outperform” rating and issued a $21.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, April 12th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $21.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, April 12th. TheStreet raised shares of Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Friday, May 12th. Finally, HC Wainwright started coverage on shares of Vanda Pharmaceuticals in a research note on Friday, May 26th. They issued a “buy” rating and a $18.00 target price for the company. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $21.22.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.